Immune checkpoint - CTLA-4 PD-1 2
|
|
|
- あつとし やすこ
- 5 years ago
- Views:
Transcription
1 CTLA-4 / PD-1 / PD-L1
2 Immune checkpoint - CTLA-4 PD-1 2
3 ACRO Biosystems ACRO Biosystems HEK293 Human PD-1 / PDCD1 Protein, Tag Free, Full Length PD-1 PD-1 ECD ACRO Biosystems 7 PD-1 PD-1 PD-1 His PD-1 ECD PD-L1 PD-1 A representative ELISA result showed that immobilized full length human PD1 PD1-HC214, 20 ng/well can bind with human PDL1 with a linear range of ng, which is much higher than the PD1 ECD protein linear range 250ng-1,250ng. Human PD-1/PDCD1 Protein, Tag Free, Full Length Leu 25 - Leu 288 PD1-HC µg 135,000 PD-1 Cynomolgus Leu 25 - Gln 167 His Tag PD1-C µg 113,000 1 mg 800,000 PD-1 Cynomolgus Leu 25 - Gln 167 Fc Tag PD1-C µg 75,000 PD-1 Human Leu 25 - Gln 167 His Tag PD1-H µg 75,000 1 mg 495,000 PD-1 Human Leu 25 - Gln 167 Fc Tag PD1-H µg 75,000 1 mg 500,000 PD-1 Human Leu 25 - Gln 167 Strep Tag PD1-H µg 65, µg 220,000 PD-1 Biotin Human Leu 25 - Gln 167 His Tag & Avi Tag PD1-H82E4 PD-1 Biotin Human Leu 25 - Gln 167 Fc Tag & Avi Tag PD1-H82F1 PD-1 Biotin Human Leu 25 - Gln 167 His Tag & Fc Tag & Avi Tag PD1-H82F2 PD-1 Human Leu 25 - Leu 288 PD1-HC µg 135,000 PD-1 Mouse Ser 21 - Gln 167 mouse IgG2a Fc Tag PD1-M52A4 3
4 PD-1 Mouse Leu 25 - Gln 167 His Tag PD1-M µg 63,000 PD-1 Mouse Leu 25 - Gln 167 Fc Tag PD1-M µg 88,000 1 mg 495,000 PD-1 Biotin Mouse Leu 25 - Gln 167 Fc Tag & Avi Tag PD1-M82F4 PD-1 Rat Leu 25 - Gln 167 Fc Tag PD1-R5253 PD-1 Rat Leu 25 - Gln 167 His Tag PD1-R52H2 100 µg 75,000 PD-1 Rabbit Leu 25 - Gln 167 His Tag PD1-R52H0 100 µg 103,000 1 mg 550,000 PD-1 Rabbit Leu 25 - Gln 167 Fc Tag PD1-RB µg 103,000 PD-L1 Cynomolgus Phe 19 - Arg 238 Fc Tag PD1-C µg 88,000 1 mg 495,000 PD-L1 Cynomolgus Phe 19 - Arg 238 His Tag PD1-C52H4 100 µg 88,000 1 mg 495,000 PD-L1 Human Phe 19 - Arg 238 His Tag PD1-H µg 75,000 1 mg 500,000 PD-L1 Human Phe 19 - Arg 238 Fc Tag PD1-H mg 525,000 PD-L1 Human Phe 19 - Arg 238 Strep Tag PD1-H µg 65, µg 220,000 PD-L1 Human Phe 19 - Arg 238 Mouse Fc Tag PD1-H52A3 100 µg 70,000 1 mg 400,000 PD-L1 Biotin Human Phe 19 - Arg 238 His Tag & Avi Tag PD1-H82E5 PD-L1 Biotin Human Phe 19 - Arg 238 Fc Tag & Avi Tag PDL-H82F2 PD-L1 Biotin Human Phe 19 - Arg 238 His Tag & Fc Tag & Avi Tag PD1-H82F3 PD-L1 C13 and N15 Human Phe 19 - Arg 238 His Tag PD1-H µg 198, µg 363,000 PD-L1 Mouse Phe 19 - Thr 238 His Tag PD1-M µg 78,000 PD-L1 Mouse Phe 19 - Thr 238 Fc Tag PD1-M µg 68,000 1 mg 300,000 PD-L1 Mouse Phe 19 - Thr 238 Mouse Fc Tag PD1-M52A2 100 µg 88,000 1 mg 525,000 PD-L1 Biotin Mouse Phe 19 - Thr 238 Fc Tag & Avi Tag PD1-M82F5 PD-L2 Human Leu 20 - Pro 219 His Tag PD2-H µg 65,000 1 mg 400,000 PD-L2 Human Leu 20 - Pro 219 Fc Tag PD2-H µg 65,000 1 mg 425,000 PD-L2 Human Leu 20 - Pro 219 Mouse Fc Tag PD2-H52A5 PD-L2 Biotin Human Leu 20 - Pro 219 His Tag & Avi Tag PD2-H82E8 PD-L2 Mouse Leu 20 - Arg 219 Fc Tag PD2-M5254 1mg 450,000 PD-L2 Mouse Leu 20 - Arg 219 mouse IgG2a Fc Tag PD2-M52A5 1mg 450,000 PD-L2 Mouse Leu 20 - Arg 219 His Tag PD2-M52E3 4
![PD1 / PD-L1 Inhibitor Screening Kits ELISA ACRO Biosystems PD-1 / PD-L1 ELISA PD1 PDL1 PD-1[Biotin]:PD-L1 Inhibitor Screening Pair EP-101 96 Tests 150,000 PD-1[Biotin]:PD-L1 Inhibitor Screening Pair](/docs-images/89/99954296/images/5-2.jpg "EP-101 480 Tests 538,000 PD-1 PD-L1 HEK293 PD-1 PD-1 PD-1 PD1-NA001 Immobilized human PD-L1 protein Catalog# A001-214 at 2µg/mL 100 µl/well can bind biotinylated human PD-1 Catalog# A002-214 with a")
5 PD1 / PD-L1 Inhibitor Screening Kits ELISA ACRO Biosystems PD-1 / PD-L1 ELISA PD1 PDL1 PD-1[Biotin]:PD-L1 Inhibitor Screening Pair EP Tests 150,000 PD-1[Biotin]:PD-L1 Inhibitor Screening Pair EP Tests 538,000 PD-1 PD-L1 HEK293 PD-1 PD-1 PD-1 PD1-NA001 Immobilized human PD-L1 protein Catalog# A at 2µg/mL 100 µl/well can bind biotinylated human PD-1 Catalog# A with a linear range of µg/mL when detected by Streptavidin-HRP Catalog# A Inhibition of PD-1-PD-L1 binding by Anti-PD-1 neutralizing antibody Catalog # PD1-NA001 measured using the PD-1 [Biotinylated] : PD-L1 Inhibitor Screening ELISA Assay Pair Catalog # EP Tests 480Tests Human PD-L1 A µg 125 µg Human PD-1-Biotin A µg 25 µg Streptavidin-HRP A µg 25 µg Anti-PD-1 Neutralizing Antibody PD1-NA µg 100 µg 5
6 BioXCell In Vivo BioXCell in vivo InVivoMab EU/µg 95 CTLA-4 CD152 human BN13 Mouse IgG2a, κ Neu, FC BE0190 CTLA-4 CD152 mouse UC10-4F10-11 Armenian Hamster IgG Neu, WB, FC BE0032 CTLA-4 CD152 mouse 9H10 Syrian Hamster IgG Neu, WB BE0131 CTLA-4 CD152 mouse 9D9 Mouse IgG2b Neu, WB BE0164 PD-1 CD279 human J116 Mouse IgG1, κ BL, Neu BE0188 PD-1 CD279 human J110 Mouse IgG1 FC BE0193 PD-1 CD279 mouse J43 Armenian Hamster IgG BL, Neu, WB BE PD-1 CD279 mouse RMP1-14 Rat IgG2a, κ BL, WB BE0146 PD-1 CD279 mouse 29F.1A12 Rat IgG2a, κ BL, Neu, IHC(Fr), IF, WB, FC BE0273 PD-L1 B7-H1 human 29E.2A3 Mouse IgG2b, κ BL, FA, IHC(Fr), FC BE0285 PD-L1 B7-H1 mouse 10F.9G2 Rat IgG2b, κ BL, IHC(Fr), IF, WB, FC BE0101 PD-L2 B7-DC mouse TY25 Rat IgG2a, κ BL, IHC(Fr), FC BE0112 BL Neu FA IHC IF WB FC BE0032 BE BE0112 BE0164 BE0188 BE0190 BE0193 BE0273 BE mg 42,000 33,000 5 mg 115,000 83, mg 287, , mg 438, , mg 626, ,000 BE0101 BE0131 BE mg 42,000 33,000 5 mg 122,000 83, mg 339, , mg 501, , mg 741, ,000 6
7 BioXCell InVivoPlus Bio X Cell InVivoMab InVivoPlus EU/µg 95 5 FACS ELISA CTLA-4 CD152 mouse UC10-4F10-11 Armenian Hamster IgG Neu, WB, FC BP0032 CTLA-4 CD152 mouse 9D9 Mouse IgG2b Neu, WB BP0164 CTLA-4 CD152 mouse 9H10 Syrian Hamster IgG Neu, WB BP0131 PD-1 CD279 mouse J43 Armenian Hamster IgG BL, Neu, WB BP PD-1 CD279 mouse RMP1-14 Rat IgG2a, κ BL, WB BP0146 PD-1 CD279 mouse 29F.1A12 Rat IgG2a, κ BL, Neu, IHC(Fr), IF, WB, FC BP0273 PD-L1 B7-H1 mouse 10F.9G2 Rat IgG2b, κ BL, IHC(Fr), IF, WB, FC BP0101 BL Neu FA IHC IF WB FC BP0032 BP BP0164 BP mg 143, , mg 365, , mg 561, , mg 800, ,000 BP0101 BP0131 BP mg 153, , mg 433, , mg 642, , mg 951, ,000 in vivo BioXCell PBS 1X InVivoPlus InVivoMab InVivoPure Dilution Buffers EU/ug InVivoPure ph 6.5 Dilution Buffer IP ml 18,000 12,000 InVivoPure ph 7.0 Dilution Buffer IP ml 18,000 12,000 InVivoPure ph 8.0 Dilution Buffer IP ml 18,000 12,000 InVivoPure ph 6.0T Dilution Buffer 0.01% TWEEN 80 IPT ml 18,000 12,000 InVivoPure ph 6.5T Dilution Buffer 0.01% TWEEN 80 IPT ml 18,000 12,000 InVivoPure ph 8.0T Dilution Buffer 0.01% TWEEN 80 IPT ml 18,000 12,000 6 BioXCell TEL
8 BioXCell IgG Human IgG IgG Fc in vivo ELISA, WB, IF, IHC, IP, FCM InVivoPure ph 7.0 Dilution Buffer P7 InVivoPlus Human IgG1 Isotype control 5 mg, 25 mg, 50 mg, 100 mg BP0297 InVivoPlus Human IgG2 Isotype control 5 mg, 25 mg, 50 mg, 100 mg BP0301 InVivoMab Human IgG1 Isotype control 1 mg, 5 mg, 25 mg, 50 mg, 100 mg BE0297 InVivoMab Human IgG2 Isotype control 1 mg, 5 mg, 25 mg, 50 mg, 100 mg BE0301 InVivoPlus Mouse IgG1 Isotype control; Unknown Specificity MOPC-21 5 mg, 25 mg, 50 mg, 100 mg BP0083 InVivoPlus Mouse IgG2a Isotype control; Unknown Specificity C mg, 25 mg, 50 mg, 100 mg BP0085 InVivoPlus Mouse IgG2b Isotype control; Unknown Specificity MPC-11 5 mg, 25 mg, 50 mg, 100 mg BP0086 InVivoPlus Rat IgG1 Isotype control; anti Horseradish Peroxidase HRPN 5 mg, 25 mg, 50 mg, 100 mg BP0088 InVivoPlus Rat IgG1 Isotype control; anti Trinitrophenol TNP6A7 5 mg, 25 mg, 50 mg, 100 mg BP0290 InVivoPlus Rat IgG2a Isotype control; anti Trinitrophenol 2A3 5 mg, 25 mg, 50 mg, 100 mg BP0089 InVivoPlus Rat IgG2b Isotype control; anti KLH LTF-2 5 mg, 25 mg, 50 mg, 100 mg BP0090 InVivoPlus Polyclonal Armenian Hamster IgG Polyclonal 5 mg, 25 mg, 50 mg, 100 mg BP0091 InVivoPlus Polyclonal Syrian Hamster IgG Polyclonal 5 mg, 25 mg, 50 mg, 100 mg BP0087 InVivoMab Armenian Hamster IgG Isotype control; anti GST PIP 1 mg, 5 mg, 25 mg, 50 mg, 100 mg BE0260 InVivoMab Mouse IgG1 Isotype control; Unknown Specificity MOPC-21 1 mg, 5 mg, 25 mg, 50 mg, 100 mg BE0083 InVivoMab Mouse IgG2a Isotype control; Unknown Specificity C mg, 5 mg, 25 mg, 50 mg, 100 mg BE0085 InVivoMab Mouse IgG2b Isotype control; Unknown Specificity MPC-11 1 mg, 5 mg, 25 mg, 50 mg, 100 mg BE0086 InVivoMab Rat IgG1 Isotype control; anti Horseradish Peroxidase HRPN 1 mg, 5 mg, 25 mg, 50 mg, 100 mg BE0088 InVivoMab Rat IgG1 Isotype control; anti Trinitrophenol TNP6A7 1 mg, 5 mg, 25 mg, 50 mg, 100 mg BE0290 InVivoMab Rat IgG2a Isotype control; anti Trinitrophenol 2A3 1 mg, 5 mg, 25 mg, 50 mg, 100 mg BE0089 InVivoMab Rat IgG2b Isotype control; anti KLH LTF-2 1 mg, 5 mg, 25 mg, 50 mg, 100 mg BE0090 InVivoMab Polyclonal Armenian Hamster IgG Polyclonal 1 mg, 5 mg, 25 mg, 50 mg, 100 mg BE0091 InVivoMab Polyclonal Hamster IgG f(ab')2 Fragments Polyclonal 1 mg, 5 mg, 25 mg, 50 mg, 100 mg BE0091-FAB InVivoMab Polyclonal Goat IgG Polyclonal 1 mg, 5 mg, 25 mg, 50 mg, 100 mg BE0130 InVivoMab Polyclonal Human IgG Polyclonal 1 mg, 5 mg, 25 mg, 50 mg, 100 mg BE0092 InVivoMab Polyclonal Mouse IgG Polyclonal 1 mg, 5 mg, 25 mg, 50 mg, 100 mg BE0093 InVivoMab Polyclonal Rabbit IgG Polyclonal 1 mg, 5 mg, 25 mg, 50 mg, 100 mg BE0095 InVivoMab Polyclonal Rat IgG Polyclonal 1 mg, 5 mg, 25 mg, 50 mg, 100 mg BE0094 InVivoMab Polyclonal Syrian Hamster IgG Polyclonal 1 mg, 5 mg, 25 mg, 50 mg, 100 mg BE0087 InVivoMab Recombinant Human IgG1 Fc Human Fc-G1 1 mg, 5 mg, 25 mg, 50 mg, 100 mg BE0096 InVivoMab Recombinant Mouse IgG2a Fc Mouse Fc-G2a 1 mg, 5 mg, 25 mg, 50 mg, 100 mg BE0097 InVivoPlus Isotype Control 5 mg 143, , mg 365, , mg 561, , mg 800, ,000 BE0091-FAB 5 mg 188, , mg 318, , mg 522, , mg 730, ,000 InVivoMab Isotype Control 1 mg 42,000 33,000 5 mg 115,000 83, mg 287, , mg 438, , mg 626, ,000 8
9 Matriks Biotechnology ADA ELISA Matriks Biotechnology Anti- Drug Antibody, ADA ELISA ADA CTLA-4, PD-1, PD-L1 ADA ELISA Cmax-Cmin 10ul~ ready-to-use ADA ELISA ELISA Avelumab Bavencio SHIKARI Q-AVE TR-Q-AVEV1 1 Kit 193,000 Nivolumab Opdivo SHIKARI Q-NIVO TR-Q-NIVOV1 1 Kit 193,000 Pembrolizumab Keytruda SHIKARI Q-PEM TR-PEMV1 1 Kit 207,000 Ipilimumab Yervoy SHIKARI Q-IPI TR-IPIV1 1 Kit 207,000 ADA ELISA Antibodies to Avelumab Bavencio SHIKARI S-ATAV TR-A-AVEV1 1 Kit 193,000 Antibodies to Nivolumab Opdivo SHIKARI S-ATN TR-ATNV1 1 Kit 193,000 Antibodies to Pembrolizumab Keytruda SHIKARI S-ATP TR-A-PEMV1 1 Kit 193,000 Antibodies to Ipilimumab Yervoy SHIKARI S-ATI TR-AIPIV1 1 Kit 193,000 9
10 Sino Biological Sino Biological FCM assay for PD-L1 antibody IHC assay for PD-L1 antibody WB assay for CTLA-4 antibody Flow Cytometry analysis of PD-L1 antibody R401 reacting on mouse splenocytes. Immunohistochemical analysis of paraffin-embedded human placenta using PD-L1 antibody R015 at 5µg/mL. Western Blot analysis of CTLA4 antibody (11159-RP02, 1:500 dilution) measured using Jurkat Membrane Lysate (20µg/lane). Human CTLA-4 / CD152 Antibody, Rabbit PAb WB, ELISA RP µg 38,000 Human PD1 / PDCD1 Antibody, Rabbit MAb ELISA R µg 58,000 Mouse PD1 / PDCD1 / CD279 Antibody, Rabbit PAb ELISA, IHC-P RP µg 58,000 Human PD-L1 / B7-H1 / CD274 Antibody, Rabbit MAb ELISA, IHC-P R µg 58,000 Mouse PD-L1 / B7-H1 / CD274 Antibody, Rabbit MAb FCM R µg 58,000 Human B7-H5 / GI24 / VISTA Antibody, Rabbit PAb ELISA T µg 58,000 Human CD40 / TNFRSF5 Antibody, Mouse MAb ICC/IF, IF, FCM MM µg 58,000 Human CD80 / B7-1 Antibody, Rabbit PAb WB, ELISA, IHC-P T µg 38,000 Human CD155 / PVR / NECL5 Antibody, Rabbit MAb WB, ELISA, IP R µg 58,000 Mouse CD155 / PVR Antibody, Rabbit MAb ICC/IF, IF, FCM R µg 58,000 Human CEACAM1 / CD66a Antibody PE, Rabbit MAb FCM R103-P 100 Tests 48,000 Mouse CEACAM1 / CD66a Antibody, Rabbit MAb IHC-P R µg 50,000 Mouse TIGIT / VSTM3 Antibody, Rabbit PAb ELISA, IHC-P T µg 38,000 Human TIM-3 / HAVCR2 Antibody, Rabbit MAb ELISA R µg 58,000 10
11 Sino Biological Sino Biological cdna High purity < 1 EU/µg His Fc Validated activity 3.0 Human ICOS Ligand Protein (His Tag) 2.5 Abs.(OD450nm-Blank) E-4 1E Human ICOS Protein (His & Fc Tag) Con.(ug/ml) The purity of PD-L H02H was >95% as determined by SDS-PAGE. The activity assay of ICOS Ligand protein Cat: H08H by binding to ICOS Protein Cat: H03H. EC50= 0.30µg/ml Human CTLA4 / CD152 Protein His Tag H08H 100 µg 32,000 Human PD1 / PDCD1 Protein His Tag H08H 100 µg 45,000 Human PD-L1 / B7-H1 / CD274 Protein Fc Tag H02H 100 µg 45,000 Human PD-L1 / B7-H1 / CD274 Protein His Tag H08H 100 µg 45,000 Human 4-1BBL / CD137L Protein Fc Tag, ECD H01H 20 µg 35,000 Human B7-H5 / Gi24 / VISTA Protein His Tag H08H 50 µg 45,000 Mouse B7-H5 / GI24 / VISTA Protein ECD, His Tag M08H 50 µg 45,000 Human BTLA Protein Fc Tag H02H 50 µg 45,000 Human CD80 / B7-1 Protein His Tag H08H 100 µg 50,000 Human CD86 / B7-2 Protein His Tag H08H 100 µg 50,000 Human CD137 / 4-1BB / TNFRSF9 Protein His Tag H08H 100 µg 45,000 Human CD155 / PVR / NECL5 Protein Fc Tag H02H 50 µg 45,000 Human GITR / TNFRSF18 Protein His Tag, ECD H08H 100 µg 45,000 Human ICOS / AILIM / CD278 Protein His & Fc Tag H03H 50 µg 45,000 Human LAG3 / CD223 / Lymphocyte activation gene 3 Protein Fc Tag H02H 50 µg 45,000 Human TIGIT / VSTM3 Protein His Tag H08H 10 µg 45,000 Human TIM-3 / HAVCR2 Protein His Tag H08H 50 µg 50,000 Human TNFRSF4 / OX40 / CD134 Protein His Tag H08H 50 µg 45,000 11
12 Cloud-Clone ELISA Cloud-Clone ELISA 10 4,000 8,000 ELISA CTLA-4 / PD-1 / PD-L1 / PD-L2 ELISA Human Cytotoxic T-Lymphocyte Associated Antigen 4 / CTLA4 ELISA Kit Human PD-1 / Programmed Cell Death Protein 1 / PDCD1 ELISA Kit Human PD-L1 / Programmed Cell Death Protein 1 Ligand 1 / PDCD1LG1 ELISA Kit Human PD-L2 / Programmed Cell Death Protein 1 Ligand 2 / PDCD1LG2 ELISA Kit ,000 pg/ml 12.4 pg/ml SEB230HU 96 Test 127, ng/ml ng/ml SEA751HU 96 Test 120, ng/ml ng/ml SEA788HU 96 Test 120, ng/ml ng/ml SEA789HU 96 Test 120,600 SEA788HU PMID: # Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications Chin J Cancer Res Feb; 26 1 : PMID: # High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. Leukemia Dec;28 12 : PMID: # PD-L1 gene polymorphisms and low serum level of PD-L1 protein are associated to type 1 diabetes in Chile. Diabetes Metab Res Rev Nov;30 8 : PMID: # Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study. Lancet Haematol Oct;2 10 :e PMID: # High levels of the soluble programmed death-ligand spd-l1 identify hepatocellular carcinoma patients with a poor prognosis. Eur J Cancer May;59: SEA789HU PMID: # Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer. J Cancer Res Clin Oncol Aug;142 8 : IWAI CHEMICALS COMPANY TEL FAX TEL FAX TEL FAX TEL TEL TEL TEL TEL TEL FAX
170920_BioXCell社カタログ改訂2【9校】.indd
BULK ANTIBODIES for in vivo RESEARCH Bio X Cell in vivo InVivoPlus 0.001 EU/ug 95 5 FACS ELISA 4-1BB CD137 Mouse LOB12.3 Rat IgG1 4-1BB activation BP0169 CD3 ε Mouse 145-2C11 Armenian Hamster IgG1 DP,
BE0005 TS-1/ InVivoMab anti-human LFA-1α (CD11a) mouse IgG , ,000 BE0005 TS-1/ InVivoMab anti-human LFA-1α (CD11a) mous
Bio X Cell 社価格表 (2018 年 4 月 ) < 株式会社シン コーポレーション > Bio X Cell 社価格表 (2018 年 4 月 ) ご注文ごとに別途取扱手数料 (2( 万円 税別 ) を申し受けます 大学向け価格でのご購入には アカデミックプライス適用申込書のご提出が必須となります 品番クローン品名イソタイプ 容量 (mg) 大学向希望小売価格 ( 円 ) 税別 希望小売価格
エピトープタグ抗体製品リスト PM020 Anti-DDDDK-tag pab Polyclonal Rabbit Ig (aff.) WB, IP, IC 100 ml 15,000 PM020-7 Anti-DDDDK-tag pab HRP-DirecT Polyclonal Rabbit I
(kda) 150 100 DDDDK-tagged protein 75 50 37 IgG Heavy chain 25 20 IgG Light chain Sample: N-terminal DDDDK-tagged β-gal protein transfectant μ μ μ http://ruo.mbl.co.jp/ エピトープタグ抗体製品リスト PM020 Anti-DDDDK-tag
PowerPoint プレゼンテーション
Isotype 略語紹介 AF 488 Alexa Fluor 488 AF 594 Alexa Fluor 594 AF 647 Alexa Fluor 647 AF 700 Alexa Fluor 700 BV 421 Brilliant Violet 421 BV 510 Brilliant Violet 510 BV 570 Brilliant Violet 570 BV 605 Brilliant
190117_Quidel社カタログ改訂【初校】.indd
RESEARCH KITS AND REAGENTS Quidel 1979 1984 MicroVue 2016 3 Immutopics MicroVue 50 ISO 13485:2003 ELISA Quidel Specialty Products is the option for all your research, biosafety and cytotoxicity testing
ROWCatPathology_J.book
www.dako.jp IHC Solution Visualization Systems Number of Steps 5 4 3 2 1 LSAB TM 2 EnVision TM G 2 Doublestain EnVision TM DuoFLEX Doublestain LSAB TM + EnVision TM G 2 EnVision TM + EnVision TM FLEX 1
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3
VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3 2 OptiView ALK D5F3 11 10 79.3%31% 18% 80 85NSCLC 40% 1,2 1 1018 ALK ALK 2 ALK 3 5% ALK EML4 EML4-ALK Coild-Coil ALK ALK 3,4,5 2 6 EGFR 50%
semen quality or those without WBC in semen. In the patients with azoospermia and normal FSH levels (normogonadotropic azzospermia), the antibody (IgG
CLINICAL STUDIES OF UROGENITAL INFECTIONS WITH CHLAMYDIA TRACHOMA TIS Report 2. The Epidemiology of Chlamydial Infections in Okayama District in Japan and Detection of Antibodies to Chlamydiae in the Sera
Anti-dimethyl Histone H3 (Lys9)
MAB Institute, Inc. 82 Inaokacho, Yokosuka-shi, Kanagawa 238-8580, Japan TEL, FAX: +81 46-822-9328 Anti- Histone H3 (Lys36), mouse monoclonal antibody Catalog No. MABI0332-20, MABI0332-100 Lot No. 11001
能書単頁9[1].5(2)
![能書単頁9[1].5(2)](/thumbs/87/96620151.jpg "能書単頁9[1].5(2)")
ips CytoTune -ips ver.1.0 1 I CytoTune ips 3 II 3 3 4 5 III CytoTune ips ips 6 6 6 6 7 1) 2) ips 8 ips 8 SeV 9 SeV 10 IV Q&A 11 V 12 12 VI...13 13...13 2 I CytoTune ips CytoTune ips 4 OCT3/4SOX2 KLF4c
プロトコール集 ( 研究用試薬 ) < 目次 > 免疫組織染色手順 ( 前処理なし ) p2 免疫組織染色手順 ( マイクロウェーブ前処理 ) p3 免疫組織染色手順 ( オートクレーブ前処理 ) p4 免疫組織染色手順 ( トリプシン前処理 ) p5 免疫組織染色手順 ( ギ酸処理 ) p6 免疫
< 目次 > 免疫組織染色手順 ( 前処理なし ) p2 免疫組織染色手順 ( マイクロウェーブ前処理 ) p3 免疫組織染色手順 ( オートクレーブ前処理 ) p4 免疫組織染色手順 ( トリプシン前処理 ) p5 免疫組織染色手順 ( ギ酸処理 ) p6 免疫組織染色手順 ( ギ酸処理後 マイクロウェーブまたはオートクレーブ処理 )p7 抗原ペプチドによる抗体吸収試験 p8 ウエスタン ブロッティング
untitled
T DAC8 2011 1 27 (DAC) DAC 11 DAC8 DAC8 T Leukemia. 2008, 22, 1026 1134. Clin. Cancer. Res. 2009, 15, 91 99. DAC8 1)DAC8 2) T T T-ALL 10 1 T-ALL 30~40% T CTCL 10 1 CTCL T ATLL 1 TLV-1 120 2,000 TLV-1 16~41%
Ab-Match Assembly Human PAP1 (REG3a) Kit
CODE No. 323 For Research Use Only, Not for use in diagnostic procedures. Ab-Match Assembly Human PAP1 (REG3α) Kit For technical material or related information, please refer to http://ruo.mbl.co.jp/product/abmatch/abmatch.html.
A, B 2 B 5 A C A ADP A G ADP ADP G camp B GM A B CTB Tochikubo et al., 1998 CTB CTB Dertzbaugh & Elson, 1993a; Yu et al., 1994; Shi et al., 1995 CTB C
2004 Analysis of the expression of cholera toxin B-subunit gene 1065010 2004 8 26 1 A, B 2 B 5 A C A ADP A G ADP ADP G camp B GM A B CTB Tochikubo et al., 1998 CTB CTB Dertzbaugh & Elson, 1993a; Yu et
,328 C 6426 H 9900 N 1700 O 2008 S , ,
2458 13 4 24 1 11 9 17 1,328 C 6426 H 9900 N 1700 O 2008 S 44 145,000 148,000 10 11 27 2 13 4 24 11 9 17 (1) CD20 B CD20 (2) infusion reaction infusion-associated symptom CD20 B 1 375mg/m 2 1 4 3 Heavy
日本組織適合性学会誌第20巻2号
Major Histocompatibility Complex 2013; 20 (2): 121 129 平成 25 年度認定 HLA 検査技術者講習会テキスト HLA 1) 1) HLA HLA HLA PRA Panel reactive antibody DSA Donor specific alloantibody class subclass non-hla HLA キーワード :Human
おすすめのローディング コントロール抗体 ターゲット 免疫動物 * モノ M ポリ P 交差性 * 製品番号 Actin Rb P Ms, Rat, Chk, Cow, Hu, Xl,Dm, Zfsh ab1801 alpha sarcomeric Actin Ms M Hu, Ms, Rat ab
ローディング コントロール抗体 アブカムならあなたにぴったりの コントロール抗体 が見つかるはずです ローディング コントロール抗体 (Loading control antibody) は ウエスタン ブロッティングにおけるポジティブ コントロールとなる抗体で 各レーンのサンプルが均等に泳動されていることの確認 ゲルからメンブレンへ確実に転写されていることの確認 また異なるサンプル中のターゲット
研究成果報告書(基金分)
DNA cdna mrna DNA ( /) (PS) (PS-tag: RIIIRRIRR) PS scfv PS-tag PS-tag scfv (PMMA)(PC) -S- (GST)PC PMMA GST GST PMMA-tag: DVEGIGDVDLVNYFEVGAT- YTFNK PC-tag: NSNFFGLVDGLNF- AVQYLGK) -S- PS-tag PMMA-tagPC-tag
第79回_プログラム.indd
Regulation of ghrelin signaling by a leptin-induced gene, negative regulatory element-binding protein, in the hypothalamic neurons. Phase I clinical trial using peptide vaccine for human vascular endothelial
欧州に見るマイナス金利が銀行に及ぼす影響
TEL 3-6733-17 E-mail 1 / 14 216 5 27 TEL 3-6733-17 E-mail 2 / 14 EU 2161 2146 2152 2127 2149 21412 2163 216 3.1%.1%...5%.6% 1.25%.65% CD.75%.5% 1.45% 1.2% 1 (2164 ).82%.97%.62%.51%.259% 3.325% 2161 1 6,4
ÿþ
TNF ファミリー 腫瘍壊死因子 ( Tumor Necrosis Factor: TNF) は 固形がんに対して出血性の壊死を誘導する因子として発見されたサイトカインです TNF ファミリーには TNF-α リンフォトキシンα Fas リガンドや TRAIL などのアポトーシス誘導に関与するサイトカインのほか RANK リガンド OX40 リガンド APRIL など 20 種類近くに因子が同定されています
MONOCLONAL ANTIBODY
MONOCLONAL ANTIBODY For research use only. Not for clinical diagnosis. Catalog No. MCA-MABI0323-100-EX Anti-Histone H3 (Lys27), mouse monoclonal antibody Product type Host Source Primary antibodies Culture
H1-P15
72 January 2009 72 January 2009 72 January 2009 2008 GFP GFP 1992 Prasher cdna GFP Aequorea victoria GFP cdna in vivo EGFP GFP FACS GFP GFP GFP GFP 1. Prasher, D.C., et al. 1992. Primary structure of the
<8DD AA97A3834C B BF8A69838A C8EA E786C7378>
ST-01738 ErythroClear Red Blood Cell Depletion Reagent kit 臍帯血 2 ml 用 17,000 13,600 ST-01739 ErythroClear Red Blood Cell Depletion kit 臍帯血 2 ml 用 475,000 380,000 ST-07801 Lymphoprep 250 ml 17,000 13,600
日本消化器外科学会雑誌第29巻第9号
Table 1 Oligonucleotide primers used for RT-PCR and internal probes used for Southern blot hybridization Cytokine Primer Sequence (5'-3') 5' 3' Internal probe s' 3' Internal probe 5' 3' Internal probe
Medical Journal of Aizawa Hospital Medical Journal of Aizawa Hospital Vol. 10 (2012) Key words ö γ µ Graves disease and Hashimoto s thyroiditis are autoimmune thyroid diseases. Graves disease causes
DiovNT
Peptide Antisera and Monoclonal Antibodies (2) Antisera of Yanaihara Institute Inc. Monoclonal Antibodies Peptide Antisera and Antisera of Yanaihara Institute Inc. 274 Manufacturer: YANAIHARA INSTITUTE
988 CHEMOTHERAPY NOV. 1971
988 CHEMOTHERAPY NOV. 1971 VOL. 19 NO. 8 CHEMOTHERAPY 989 Effect of medium-ph and inoculum size on activity of SB-PC heart infusion agar, mcg/ml Sensitivity distribution of Staphylococci to SB-PC in surgical
Key words : Adverse reactions, Egg allergy, IgG antibody, Mills allergy, FAST
Key words : Adverse reactions, Egg allergy, IgG antibody, Mills allergy, FAST 13) Danaeus, A., Johansson, S. G. O., Foucard, T. & Ohman, S.: Clinical and immunogical aspects of food allergy in childhood.
CHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09330)
CHEMOTHERAPY APR. 1982 Fig. 1 Chemical structure of cefotetan (CTT, YM09330) VOL.30 S-1 CHEMOTHERAPY Fig. 2 Comparison of standard curves of CTT on various test organisms by cylinder plate method Column
(Quality of Life; QL) QL (Nerve Growth Factor; NGF) NGF PC12 6- (6-HITC) NGF NGF NGF PTP1B 6-HITC PTP1B NGF PTP1B 6-HITC PTP1B 6-HITC NGF 6-HITC 6-HITC in vivo 464-8601 Tel: 052-789-4126 20-Hydroxyecdysone
CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates
VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak
Endocrinological and statistical analysis of ovarian function in hysterectomized patients Masaya HAYAFUJI, Kazuaki KATAYAMA and Matsuto MOCHIZUKI Depa
Endocrinological and statistical analysis of ovarian function in hysterectomized patients Masaya HAYAFUJI, Kazuaki KATAYAMA and Matsuto MOCHIZUKI Department of Obstetrics and Gynecology, Kobe University
STUDIES ON THE RELATION BETWEEN LATE DUMPING SYNDROME AND GLUCAGON RESPONCES TO GLUCOSE Taisuke MATSUI The First Department of Surgery, Nara Medical U
STUDIES ON THE RELATION BETWEEN LATE DUMPING SYNDROME AND GLUCAGON RESPONCES TO GLUCOSE Taisuke MATSUI The First Department of Surgery, Nara Medical University, Kashihara (Director: Prof. H. Nakano) This
Rinku General Medical Center
Rinku General Medical Center 4860 100 1620 Ann Intern Med. 1966; 64: 328 40 CHOP 63 1 83 J Clin Oncol. 1998; 16: 20065-69 Febrile Neutropenia IDSA(Infectious Diseases Society of America) 2002 Guidelines
2
1 2 3 4 5 (written by Dr. ) Stock Solution (one liter) in 4 Buffer A: 0.05 M glucose 20% (1.1 M) glucose 22.7 ml 0.025 M Tris-Cl ph8 1 M Tris (ph8.0) 12.5 ml 0.01 M EDTA 0.5 M EDTA 10 ml Buffer B: 5 M
A Nutritional Study of Anemia in Pregnancy Hematologic Characteristics in Pregnancy (Part 1) Keizo Shiraki, Fumiko Hisaoka Department of Nutrition, Sc
A Nutritional Study of Anemia in Pregnancy Hematologic Characteristics in Pregnancy (Part 1) Keizo Shiraki, Fumiko Hisaoka Department of Nutrition, School of Medicine, Tokushima University, Tokushima Fetal
DynalTransplantDiagnostic.indd
2011 1 SeCore HLA SBT 1 2 AllSet + Gold SSP HLA 7 3 SSP UniTray HLA 11 4 27 5 32 ii 1 SeCore HLA SBT SeCore 2 SeCore HLA SBT SeCore 3 SeCore 4 HLA-I 5 HLA-II 5 utype 5 GSSP 6 1 SeCore HLA SBT Sequencing
YK170 17β-Estradiol EIA キット
YK170 17 - Estradiol EIA FOR RESEARCH LABORATORY USE ONLY 418-0011 2480-1 FAX: 0544-22-2770 TEL: 0544-22-2771 Website: www.yanaihara.co.jp E-mail: ask@yanaihara.co.jp . 2. 3. 4. 5 6. 7. 8 10. 11. 11 1
Influence of Material and Thickness of the Specimen to Stress Separation of an Infrared Stress Image Kenji MACHIDA The thickness dependency of the temperature image obtained by an infrared thermography
スライド 1
1 2006 msv 2 2011 3 CT 2011 10mSv 10 40mSv 4 2012 217mSv 5 (CT) 2012 50 60mSv 6 2012 510mSv BRCA25 310 10mSv3% BRCA60-280% 3 5m Sv 1m Sv 12% . http://www.rea.or.jp/ire/pdf/report4.pdf 1.10 20 SMR 1.00
広島県獣医学会雑誌24号.indd
1 1 Study on the effects of dexamethasone administration in acute coccidiosis accompanied by bloody stools TOMOYASU KUROSE Shoubara Veterinary Clinical Center, P. F. A. M. A. A -1-, Nishihonmachi, Shoubara,
CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX
Fig. 1 Chemical structure of CXM-AX NOV. 1986 Fig. 2 Sensitivity distribution of clinical isolates organisms (106 cells/ml) a Smurcus 27 strains d) P.m irabilis 15 strains b Ecol i 27 strains 111.morganii
A study on thyroid function in patients on chronic dialysis Masahumi Kikkawa, Issei Tanaka, Naoki Haruta, Takao Hinoi, Tamaki Nakatani, Kazuaki Miyamo
A study on thyroid function in patients on chronic dialysis Masahumi Kikkawa, Issei Tanaka, Naoki Haruta, Takao Hinoi, Tamaki Nakatani, Kazuaki Miyamoto Artifical Kidney Center, Hiroshima Prefectural Hiroshima
日大 特集追加.indd
日大医誌 75 (4): 156 160 (2016) 156 特 集 免疫チェックポイント阻害薬はがんの治療の未来をどう変えるか Mechanisms of Action, Efficacy and Side Effects of Nivolumab and Its Therapeutic Use at Itabashi Hospital, Nihon University School of Medicine
Key words: HIV screening kit, window period, p24antigen, enzyme-linked fluorescent assay
Key words: HIV screening kit, window period, p24antigen, enzyme-linked fluorescent assay Fig.1 @ A principle of assay The assay comprises of two reactions. The first reaction, for the detection of anti-hiv-
A STUDY ON GENITAL SKIN ANDROGEN RECEPTOR BY DISPERSED CELL METHOD Yasukazu Sen and Masaaki Morioka Department of Urology, Kochi Medical School, Nankoku, Japan (Director: Prof. Yukitoshi Fujita) Yoshiteru
浜松医科大学紀要
On the Statistical Bias Found in the Horse Racing Data (1) Akio NODA Mathematics Abstract: The purpose of the present paper is to report what type of statistical bias the author has found in the horse
Title 歯性病巣の関連する皮膚疾患におけるビオチンの効用 Author(s) 高橋, 愼一 ; 川島, 淳子 ; 森本, 光明 ; 山根, 源之 Journal, (): - URL Right Posted at the Inst
Title 歯性病巣の関連する皮膚疾患におけるビオチンの効用 Author(s) 高橋, 愼一 ; 川島, 淳子 ; 森本, 光明 ; 山根, 源之 Journal, (): - URL http://hdl.handle.net/10130/526 Right Posted at the Institutional Resources for Unique Colle Available from
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
HOE901 A S S Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Gly
HOE901 A S S Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Gly 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 S S S Phe Val Asn Gln His Leu Cys Gly Ser His Leu
<95DB8C9288E397C389C88A E696E6462>
2011 Vol.60 No.2 p.138 147 Performance of the Japanese long-term care benefit: An International comparison based on OECD health data Mie MORIKAWA[1] Takako TSUTSUI[2] [1]National Institute of Public Health,
gtf Wnt5a-Ror2 IL-8 in vitro Ozony Tron P. gingivalis SOD ELISA Location of main occluding areas and masticatory ability in patients with reduced occlusal support 12-Methacryloyloxydodecylpyridinium bromide
Western BLoT Immuno Booster
研究用 Western BLoT Immuno Booster 説明書 v201211 Western BLoT Immuno Booster は 抗体の反応性を増強させる成分を含む溶液で 抗体の希釈液に用いるだけで 抗原抗体反応を促進します 本製品は ウェスタンブロット ELISA 等の各種イムノアッセイに対応しており 各アッセイにおいて数倍から数十倍の検出感度向上が期待できます 西洋ワサビペルオキシダーゼ
CA CA19-9 CA19-9 CA CA CA19-9 ARCHITECT i 2000SR CLIA U/mL CA % CA CA
原 著 30 22-29, 2015 CA19-9 CA19-9 CA19-9 2006 12013 6 CA19-9 32,508 37.0U/mL 790 2 CA19-9 320 CA19-9 ARCHITECT i 2000SRCLIA 0.0 37.0U/mL 8 4 1 2 18CA19-9 198.2 46.4 2,968 U/mL 5 3 2.5% CA19-9 2.5% CA19-9
H1-2_4_P01.qxd
81 J u l y 2010 81 J u l y 2010 Cosmo Bio News No.81 1 F 4 F 4 F 4 F 4 F 4 F 4 F 4 F 4 F 4 F 4 F 4 F 4 F 4 F 4 F 4 2 Cosmo Bio News No.81 http://www.cosmobio.co.jp 347 bfbfbf B 4 B 4 B 4 B 4 B 4 B 4 B
b) Gram-negative bacteria Fig. 2 Sensitivity distribution of clinical isolates : E. coli Fig. 3 Sensitivity distribution of clinical isolates : Pseudomonas Fig. 1 Sensitivity distribution of clinical isolates
センシンレンのエタノール抽出液による白血病細胞株での抗腫瘍効果の検討
Evaluation of anti-tumor activity with the treatment of ethanol extract from Andrographis Paniculata in leukemic cell lines Hidehiko Akiyama 1), Kazuharu Suzuki 2), Toshiyuki Taniguchi 2) and Itsuro Katsuda
Studies on the Antigens Expressed on Trophoblasts Related to MLR-blocking Antibodies Shigenori GOTO Department of Obstetrics and Gynecology, Niigata University School of Medicine (Director: Prof. Shoshichi
.N..
Examination of the lecture by the questionnaire of class evaluation -Analysis and proposal of result at the first term of fiscal year - Kazuo MORI, Tukasa FUKUSHIMA, Michio TAKEUCHI, Norihiro UMEDA, Katuya
AS LMD Sampling Manual
AS LMD Application Solutions LaserMicrodissection System LMD SamplingManual 2005 1 AS LMD Sampling Manual -------------------------------------------------------------2 --------------------------------------
CBA Kit Manual Human
BD Pharmingen Cytometric Bead Array (CBA) Kit Manual Human Th1/Th2 Cytokine CBA BD Biosciences Section 1 1 Multiplexing BD Cytometric Bead Array CBA Multiplexing BD CBA CBA ELISA ELISA BD Human Th1/Th2
平成１４年度 本態性多種化学物質過敏状態の調査研究 研究報告書
226 227 µ 228 Ω 229 230 0 ppb 2000ppb DG subthreshold (µa) 91 ± 59 86 ± 68 max stim. (µa) 755 ± 287 n=37 678 ± 300 max PS (mv) 8.7 ± 3.9 7.7 ± 4.3 n=61 CA1 subthreshold (µa) 36 ± 26 32 ± 13 max stim. (µa)
25 6 7 X (crystallizing ligand) Fv Fv 3.5 Co-crystallization of membrane proteins with antibody fragments may emerge as a general tool to facilitate crystal growth and improve crystal quality. The bound
116,/ / - /-, /1 /2 0 / ,, / 3 ing / , 2, 3, , 3,,. ISO. /.. 0 -,. ISO., 0-
115, -, 320 3, -,0, 0, 222,/3- Conjoint 3.., 1,/-0... 0 - Analysis 1, 1/3./. 3 / /-, - 0-,.- ha, /. 1 116,/ / - /-, /1 /2 0 / 0- - 0 2,, / 3 ing - 0. - / - - 0 -. 1 -, 2, 3, - - 3 3 31, 3,,. ISO. /.. 0
PrmryCellCltrガイド_0620.indd
初代細胞培養製品ガイド HEK HEKa C-005-5C [1Vial (>500k cells)] HEKa-APF C-021-5C [1Vial (>500k cells)] Epilife in vitro 2 Epilife 60µM CaCl 2 HEKn C-001-5C [1Vial (>500k cells)] HEKn-APF C-020-5C [1Vial (>500k cells)]
研究成果報告書
21 5 28 2007 2008 CARElk CARPXR CAR CAR EST cdna CAR CAR 10FCS 96 SW480 HepG2 anti-lamin A/C anti-phospho-histone H3 anti-cyclin D1 G1 anti-cyclin A S CAR lamin A/C CAR Fig. 1 Lamin A/C /G1 lamin A/C G1
1272 CHEMOTHERAPY MAR. 1975
1272 CHEMOTHERAPY MAR. 1975 VOL. 23 NO. 3 CHEMOTHERAPY 1273 Fig. 2 Minimal inhibitory concentration of aminoglycosides against 50 strains of Klebsiella Fig. 1 Minimal inhibitory concentration of aminoglycosides
CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote
aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Proteus mirabilis 3.13, Proteus vulgaris 1.56, Citrobacter freundii 0.39,
Table 1. Numbers of Cancerous Pleurisy Cases According to Primary Site Table 2. Histological Type of Lung Carcinoma with Cancerous Pleurisy at Autopsy
Clinicopathological Studies on Cancerous Pleurisy, with Emphasis on Extra-Pulmonary Malignancy Table 1. Numbers of Cancerous Pleurisy Cases According to Primary Site Table 2. Histological Type of Lung
Microsoft Word - CAC-CE037A_ver.2.doc
MONOCLONAL ANTIBODY For research use only. Not for clinical diagnosis. Catalog No. CE-037A Anti- Histone H3 K9Ac antibody BACKGROUND Post-translation modifications of histones modulate the accessibility
untitled
20 2 14 18 10 16 1 1.0mg 0.035mg 2 1 20 2 14 18 10 16 1 1 1 52 1 1 21 7 28 1 29 2 1 20 1 24 18 10 16 1 1 21 7 28 1 29 1 NET 1.0mg EE 0.035mg *NET *NET 1999 2007 *NET *NET 88 NSAIDs GnRH GnRH NSAIDs 20
橡
TP T-13i AST ALT ALP Y CTP LOH CHE CRP 8.7 id 0.4 mg/d 21 AWL 131U/L 257 LU/L 12 111/L 234 11J/L 344 IU/L 0.30 mid No K a BUN ORE UA 142 meq/1 4.3 meqa 108 meqa 15.8 met! 0.71 mg/di 5.0 mg/d CEA 5_5 n8/m1
1) Barat, I. u. Wagner, R.: Brauer, Beitrage Zur Klinik der Tub., Bd. 71 (1929) 2) Warnecke, F.: Zeitschr. f. Tbk. Bd. 54 (1929) 3) Leoni, Alfonso: Zbl. f. g. Tbk. Forsch. Bd. 33 (1930) 4) Jalavisto, Eva
A pp CALL College Life CD-ROM Development of CD-ROM English Teaching Materials, College Life Series, for Improving English Communica
A CALL College Life CD-ROM Development of CD-ROM English Teaching Materials, College Life Series, for Improving English Communicative Skills of Japanese College Students The purpose of the present study
ISSN 慈大 2017 feb 呼吸器疾患研究会誌 Jikei Journal of Chest Diseases 豊胸術後にシェーグレン症候群と胸膜肥厚を認めたヒトアジュバント病の 1 例花田豪郎ほか 1 第 90 回研究会記録 2 胸部 CT でスリガラス状陰影
ISSN 2189-9770 慈大 2017 feb. 29-1 呼吸器疾患研究会誌 Jikei Journal of Chest Diseases 豊胸術後にシェーグレン症候群と胸膜肥厚を認めたヒトアジュバント病の 1 例花田豪郎ほか 1 第 90 回研究会記録 2 胸部 CT でスリガラス状陰影を呈した左肺腫瘍の 1 切除例米山果織ほか 3 肺がんの新しい薬物療法 免疫チェックポイント阻害薬 滝口裕一
VOL. 37 NO. 3 Key words: Drug allergy, LMIT, Penams, Cephems, Cross-reactivity
VOL. 37 NO. 3 Key words: Drug allergy, LMIT, Penams, Cephems, Cross-reactivity CHEMOTHERAPY MAR. 1989 Mble 1. Allcrgy in parients nduced by penams VOL. 37 NO. 3 Table 2. Allergy in patients induced by
ŁRŁ¸•ñŁŁŁ‘
16 11 5 25mg 14 11 18 1 25mg 1 150,000 934 1 2 : 1-235-tumor necrosis factor receptor (human) fusion protein with 236-467-immunoglobulin G1 (human γ1-chain Fc fragment), dimmer : : 1 235 236 467 G 1 γ1
巻 頭 言
12 Lab Clin Pract. 20 2 110 114 2002 radioimmunoassay RIA enzyme linked immuno sorbent assay ELISA Immuno PCR Immuno PCR tumor necrosis factor α TNF α 1 Immuno PCR 1 1992 Sano 1) BSA streptavidin protein
VENTANA PD-L1 SP142 Rabbit Monoclonal Antibody OptiView PD-L1 SP142
VENTANA PD-L1 SP142 Rabbit Monoclonal Antibody OptiView PD-L1 SP142 2 OptiView PD-L1 SP142 OptiView PD-L1 SP142 OptiView PD-L1 SP142 PD-L1 OptiView PD-L1 SP142 PD-L1 OptiView PD-L1 SP142 PD-L1 OptiView
CAR-T実施
Building a Clinical CAR-T Program - Jichi Medical University Experience l l l Anti-CD3/28 mabs & IL-2: 29% Anti-CD3/28 beads: 66% Retroviral: 41% Lentiviral: 54% T-Flasks: 22% Static Culture Bags: 35%
Amnis TM CellStream TM CellStream TM
Amnis TM CellStream TM CellStream TM Amnis TM CellStream TM Amnis TM CCD FITC PE 5 96 7 CFR Part FDA TM CellStream Luminex Time Delay Integration TDI CellStream. 7... CCD CellStream Amnis CCD CellStream
Key words : candidemia, endotoxin, D-arabinitol, Candida antigen, serological examination
Key words : candidemia, endotoxin, D-arabinitol, Candida antigen, serological examination Fig. 1 The value of fungal index and D- arabinitol/creatinine. Fungal index was mesured by Endotoxin D and Endospecy
ON A FEW INFLUENCES OF THE DENTAL CARIES IN THE ELEMENTARY SCHOOL PUPIL BY Teruko KASAKURA, Naonobu IWAI, Sachio TAKADA Department of Hygiene, Nippon Dental College (Director: Prof. T. Niwa) The relationship
<4D F736F F D C6E30385F A B B83932E444F43>
1,2,4-1,2,4-Trimethylbenzene Pseudocumene 1,3,5-1,3,5-Trimethylbenzene Mesitylene CH 3 CH 3 CH 3 CH 3 CH 3 CH 3 1,2,4-trimethylbenzene 1,3,5-trimethylbenzene CAS 95-63-6 CAS 108-67-8 C 9 H 12 C 9 H 12
BrdU Flow Kit
BrdU FLOW KIT Kit Manual FITC -anti-brdu Antibody (Kit Component. No. 23614L) Cytofix/Cytoperm Buffer (Kit Component. No. 2090KE) Perm/Wash Buffer (10x (Kit Component. No. 2091KE) Cytoperm Plus Buffer
PDFfl[ŁiŠp_Œ{Ł¶…g…fi…{Łt‡«.pdf
診断 治療 技術講座 2018; 29 4 : 413-420 APTT 波形解析 APTT waveform Hideo WADA Key words: APTT, waveform, hemophilia, anticoagulant therapy 1978 1982 1982 1983 1985 NIH 1985 2000 / 2008 1 activated partial thromboplastin
Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents
D 012 Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents DATA : 1 DATA : 2 3 DATA : UNGITEC 1 1 DATA : 20pg/mL 1020pg/mL 10pg/mL (cut off 20pg/mL) 90.2%(37/41) 100%(85/85) 96.8%(122/126)
研究成果報告書
Functional analysis on EphB and ephrin-b expressing in gastric mucosaand their expression behavior in gastric ulcer and cancer EphBephrin-B EphBephrin-Bephrin-BEphB Gastric UnitEphB2 EphBephrin-BEphB/ephrin-B
PCR 3 Mature mirna PCR 7 miscript mirna PCR Array C T 12 Mature mirna cdna 15 miscript mirna QC PCR Array miscript mirna PCR Array 10/2011
October 2011 miscript mirna PCR Array miscript II RT Kit miscript SYBR Green PCR Kit miscript mirna PCR Arrays miscript mirna QC PCR Array Pathway-Focused mirna PCR Array mirnome miscript mirna PCR Array
Tab 5, 11 Tab 4, 10, Tab 3, 9, 15Tab 2, 8, 14 Tab 1, 7, 13 2
COMPANION 20 MULTIMEDIA SPEAKER SYSTEM Owner s Guide Tab 5, 11 Tab 4, 10, Tab 3, 9, 15Tab 2, 8, 14 Tab 1, 7, 13 2 Tab1, 7, 13 Tab 2, 8, 14 Tab 3, 9, 15 Tab 4, 10, Tab 5, 11 This product conforms to all
Key words: Antibodies to Leptospira, Tokyo, Uveitis
Key words: Antibodies to Leptospira, Tokyo, Uveitis Fig. 1 Distribution of Antibody Titers in Age Decade Fig. 3 Distribution of Antibody Titers in each Strain Fig. 2 Correlation between Antibody Titers
熊本大学学術リポジトリ Kumamoto University Repositor Title 炎症性腸疾患に対する HSF1 及び HSP70 の保護的役割 Author(s) 田中, 健一郎 Citation Issue date Type URL Thesis or Di
熊本大学学術リポジトリ Kumamoto University Repositor Title 炎症性腸疾患に対する HSF1 及び HSP70 の保護的役割 Author(s) 田中, 健一郎 Citation Issue date 2008-03-25 Type URL Thesis or Dissertation http://hdl.handle.net/2298/9448 Right 1
iQue_brochure
screening solutions for life ハイスループット セルベース スクリーニング ique Screenerによる細胞 ビーズベースアッセイ の高速解析 S S Intelliyt ique Screener ell health cell function Intelliyt ique Screener Intelliyt ique Screener ique Screener
1) Asa, S. L., et al.: Immunohistochemical localization of neuron-specific enolase in the human hypophysis and pituitary adenoma, Arch. Pathol. Lab. Med., 108: 40 `43, 1984. 2) Chi, B. H. and Kim, R. C.:
CHEMOTHERAPY FEB Table 1 Background of volunteers
CHEMOTHERAPY FEB. 1985 Table 1 Background of volunteers Table 3 Reproducibility of saisomicln In the EIA and the RIA Fig.1 Comparison of the EIA with the RIA or bioassay of sisomicin Table 4 Blood levels
CHEMOTHERAPY AUG. 1982 VOL. 30 NO. 8 CHEMOTHERAPY Fig.1 Relation between various-closis of cefazolin and detection rate of organisms in heart blood of dying mice with E. coli and P. aeruginosa infection
untitled
19 11 13 300 18 3 31 1300mg 4 6 C 15 H 22 FN 3 O 6 359.35 + -1-5--β-D--5--1,2--2- -4- 19 11 13 300 18 3 31 A B B A 30 1 2 21 7 1 1 1.31m 2 900mg 1.31m 2 1.64m 2 1,200mg 1.64m 2 1,500mg B 30 1 2 14 7 1
JIS A 5308 a1 moll moll moll (JP) REAGENT CHEMICALS ninth edition ACS SPECIFICATIONS Replication Duplicate standardiz
Measurement Uncertainty MU 1 mol/l JIS A 5308 a1 moll 1.0000.010 moll 0.001 moll (JP) 4 3 3 0.001 0.1 REAGENT CHEMICALS ninth edition ACS SPECIFICATIONS Replication Duplicate standardizations for solutions